Swiss CDMO Micro-Sphere expands capsule filling capabilities
Contract development and manufacturing organisation Micro-Sphere has invested more than €1.5 million at its plant in Switzerland to expand its offering in encapsulation for inhalation products.
Boosting its existing automatic capsule filling equipment Micro-Sphere has taken delivery of and commissioned a further two MG2 capsule filling machines to increase its low dosage filling capabilities to more than 100,000 capsules per hour.
Michael Grassberger, CEO, Micro-Sphere said: “Micro-Sphere is widely recognized for its expertise in Dry Powder Inhalation encapsulation services of difficult powder formulations. The new machinery will offer high quality products, reduced production times and cost savings for customers who want real commercial benefit.
“This investment is the result of increasing client demand. Added to our existing Harro Höfliger drum dosing equipment, the new MG2 Planeta dosator system means we are one of the few CDMOs in the world to offer these two important commercial size filling techniques under one roof and bridge the gap from development to commercial scale on both techniques for DPIs (dry powder inhalers).
“Both systems are designed for low-dosage filling and have an inline control unit (100% net weight check), FlexaLab (up to 3’000cps/hr.) that is ideal for R&D purposes and small clinical batches, and Planeta (up to 100’000cps/hr) which is scalable for medium-large batch productions. This brings more flexibility for our customers and a best-in-class approach.”
Situated in a new dedicated cleanroom at Micro-Sphere’s EU-GMP, FDA and SwissMedic approved facility near Lugano in Ticino, the MG2 equipment is in an area of controlled temperature and relative humidity of <20%, has a production capability of more than 100,000 cps/hour and increases the CDMO’s manufacturing capacity to up to 600 million capsules per year.
Alongside the MG2 Planeta machine, and for DPIs containing multiple doses, the company has also invested in increasing their containment level (OEB5) and in its DPI testing capabilities with additional Dosage Unit Sampling Apparatus (DUSA) and Next Generation Impactor (NGI).
“This investment sends a strong signal to our customers and partners by increasing our market competitiveness,” added Michael. “As the pharmaceutical industry is under increasing pressure to develop new drugs faster, we are committed to investing in the production capacity, technology and quality systems necessary to continue delivering high-quality, innovative solutions to our customers.”
The new equipment is part of the CDMO’s continued investment into expanding its GMP manufacturing capabilities and comes in response to increased demand for spray drying and inhalables from companies ranging from big pharma to small virtual firms.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company
After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. -
News PharmaKure gains authorisation for next stage testing on Alzheimer's treatment
Clinical stage pharmaceutical company PharmaKure gains permission from UK authorities to enter into further testing for PK051 for the treatment of patients with mild cognitive impairment associated with Alzheimer's disease. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News Navigating the Future: Challenges and Opportunities in Pharma Innovation and Investment – CPHI Barcelona 2023 Roundtable Report
In this comprehensive downloadable report, hear from a range of experts in finance and investment in the pharma industry on what investment trends will be shaping the future of the industry, in Catalonia, and the wider world. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance